Prevent Obesity Weight Loss Drugs CAS 136236-51-6 Rasagiline Powder

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 136236-51-6
Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 136236-51-6 Alias: Rasagiline, Rasagiline -13C3
Apparence: Almost White Crystalline Powder Purity: 99%
Stock: Enough Stock Grade: Pharma Grade
High Light:

top weight loss supplements


weight loss steroids

Product Description

Safe Medical Rasagiline Prevent Obesity Raw Material Drug CAS 136236-51-6 Powder


Quick detail

Product Name: Rasagiline

Synonyms: (R)-2,3-DIHYDRO-N-2-PROPYNYL-1H-INDEN-1-AMINE;Rasagiline -13C3;Rasagiline;(R)-N-2-Propynyl-1-indanamine;1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R);1-Indanamine, N-2-propynyl-, (R)-;Unii-003N66ts6t;(R)-N-(2-Propynyl)-2,3-dihydroinden-1-aMine

CAS: 136236-51-6

MF: C12H13N

MW: 171.24

Product Categories: ZELNORM

MOQ: 10 Gram Available
Packaging Detail:25Kg / Fiber Drum
Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Clearance Rate: 100% Custom Pass, Disguise Package and Safe

Leading Time: at the very day after payment
Delivery Time: 5-14 Working Days, Tracking Number Available
Origin Place: Hubei Province, China
Production Capacity: 500Kg/Month


Description of Rasagiline :

Rasagiline is used alone or in combination with another medication to treat the symptoms of Parkinson's disease (a slowly progressing disease of the nervous system causing a fixed face without expression, tremor at rest, slowing of movements, walking with shuffling steps, stooped posture and muscle weakness). Rasagiline is in a class of medications called monoamine oxidase (MAO) type B inhibitors. It works by increasing the amounts of certain natural substances in the brain.


How should this medicine be used?

Rasagiline comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take rasagiline at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take rasagiline exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may start you on a low dose of rasagiline and may increase your dose based upon your body's response to this medication.

Do not stop taking rasagiline without talking to your doctor. Your doctor will probably decrease your dose gradually. If you suddenly stop taking rasagiline, you may experience withdrawal symptoms such as a fever; muscle stiffness; unsteadiness, wobbliness, or lack of coordination; or changes in consciousness. Tell your doctor if you experience any of these symptoms when your dose of rasagiline is decreased.


General Dosing Recommendations

When AZILECT is prescribed as monotherapy or as adjunct therapy in patients not taking levodopa, patients may start AZILECT at the recommended dose of 1 mg administered orally once daily.

In patients taking levodopa, with or without other PD drugs (e.g., dopamineagonist, amantadine, anticholinergics), the recommended initial dose of AZILECT is 0.5 mg once daily. If the patient tolerates the daily 0.5 mg dose, but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily. When AZILECT is used in combination with levodopa, a reduction of the levodopa dose may be considered, based upon individual response.


The recommended doses of AZILECT should not be exceeded because of risk of hypertension [see WARNINGS AND PRECAUTIONS].


Patients Taking Ciprofloxacin Or Other CYP1A2 Inhibitors

Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of AZILECT 0.5 mg once daily [see WARNINGS ANDPRECAUTIONS, DRUG INTERACTIONS, and CLINICAL PHARMACOLOGY].


Patients With Hepatic Impairment

Patients with mild hepatic impairment should not exceed a dose of AZILECT 0.5 mg once daily. AZILECT should not be used in patients with moderate or severe hepatic impairment [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156